Volume 30, Supplement—October 2024
SUPPLEMENT ISSUE
Articles
Respiratory Disease Surveillance in the Middle East and Latin America during the COVID-19 Pandemic, 2020–2022
Table 1
Characteristics of samples collected as part of respiratory disease surveillance in the Middle East and Latin America during the COVID-19 pandemic, 2020–2022*
Jordan |
Latin America |
||||||
---|---|---|---|---|---|---|---|
Characteristics |
SARI, n = 8,523 |
ILI, n = 2,782 |
SARI, n = 687 |
ILI, n = 4,154 |
|||
Year of enrollment | |||||||
2020 | 909 (11) | 137 (5) | 3 (0.4) | 44 (1.1) | |||
2021 | 4,408 (52) | 1,251 (45) | 252 (37) | 2,250 (54) | |||
2022 |
3,206 (38) |
1,394 (50) |
432 (63) |
1,860 (45) |
|||
Total samples tested | |||||||
Influenza | 8,523 (100) | 2,782 (100) | 687 (100) | 4,154 (100) | |||
SARS-CoV-2 | 8,144 (96) | 2,782 (100) | 687 (100) | 4,154 (100) | |||
Other respiratory pathogens |
8,147 (96) |
2,467 (89) |
687 (100) |
4,154 (100) |
|||
Detections | |||||||
No detections | 4,446 (52.2) | 1,655 (59.5) | 116 (16.9) | 1,088 (26.2) | |||
Positive, % of positive samples | 4,077 (47.8) | 1,127 (40.5) | 571 (83.1) | 3,066 (73.8) | |||
Monodetections | 2,661 (65.3) | 721 (64.0) | 385 (67.4) | 2,609 (85.1) | |||
Codetections | 1,416 (34.7) | 406 (36.0) | 186 (32.6) | 457 (14.9) | |||
2 pathogens | 888 (21.8) | 255 (22.6) | 139 (24.3) | 388 (12.7) | |||
3 pathogens | 341 (8.4) | 104 (9.2) | 36 (6.3) | 56 (1.8) | |||
>3 pathogens | 187 (4.6) | 47 (4.2) | 11 (1.9) | 13 (0.4) |
*Samples were tested by Fast-Track Diagnostics 33 (FTD-33; Siemens Healthineers, https://www.siemens-healthineers.com) panel in Jordan and by BioFire FilmArray Respiratory Panel 2.1 (RP 2.1; bioMérieux, https://www.biomerieux.com) in Latin America. Values are no. (%). ILI, influenza-like illness; SARI, severe acute respiratory illness.
1These authors contributed equally to this article.
Page created: October 17, 2024
Page updated: November 11, 2024
Page reviewed: November 11, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.